Manuel Cobo

Hospital Regional Universitario de Málaga

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study”.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

The Lancet Oncology(2023)10.1016/s1470-2045(23)00344-3

N/A

3.1DataRank · unranked

105 citations

Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo +20 more

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

ERJ Open Research(2023)10.1183/23120541.00468-2023

N/A

0.420DataRank · unranked

10 citations

Alberto Ruano‐Raviña, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny +20 more